Pierre Fabre to boost investment in China

French pharmaceutical and dermo-cosmetics company Pierre Fabre Laboratories will continue to increase its investment and cooperation efforts in China, one of its top priority markets globally and a strategic pillar for the company's future growth, fulfilling its long-term commitment of "in China, for China", said a senior executive.

As one of the first multinational pharmaceutical companies to enter China, Pierre Fabre has consistently approached the China market with an open mindset and a commitment to long-term development. The company is confident in the future of the China market and regards the country as a key growth engine in its global strategy, said Eric Ducournau, group CEO of Pierre Fabre, one of France's leading pharmaceutical and dermo-cosmetics companies, during a recent exclusive interview in Shanghai.

"Our ambition is to be not only a participant, but a true strategic partner in China's development, and actively contribute to the country's journey toward better healthcare as per the Healthy China 2030 goals," he said.